Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Filing content

Cue Biopharma reported positive topline results from a Phase 2 clinical trial of CUE-221 in patients with chronic spontaneous urticaria conducted in China. The company plans to advance the candidate into a Phase 2b/3 trial in CSU and a Phase 2 trial in food allergy.